Can I read (1008) Gene Expression Profiling and Dd-cfdna Performance in Heart Transplant Recipients with Neuromuscular Disorders on EtoBox?

(1008) Gene Expression Profiling and Dd-cfdna Performance in Heart Transplant Recipients with Neuromuscular Disorders by L. Holzhauser; M. Molina; P. Joshi; P. Atluri; L. Goldberg; R. McLean is a scholarly article available to read on EtoBox.

What is (1008) Gene Expression Profiling and Dd-cfdna Performance in Heart Transplant Recipients with Neuromuscular Disorders about?

Purpose Donor-derived cell-free DNA (dd-cfDNA) is used to assess transplant allograft injury and rejection. Assays like AlloSure® dd-cfDNA (AS) compare the ratio of donor versus recipient cfDNA (CareDx, Inc.). We hypothesize that in neuromuscular (NM) diseases, namely muscular dystrophy (MD) and mitochondrial myopathies (MCM), the increased rate of somatic cell turnover and lack of such turnover in the allograft, would lower AS levels by increasing the recipient cf-DNA fraction. We further hypothesize that AlloMap® (AM), which assess gene expression in leukocytes, would be unaffected (CareDx, Inc.). Methods Retrospective analysis of 1362 AS results, and 1355 AM results of heart transplant (HT) recipients from 9/2018-10/2022. We compared 52 AM and 49 AS results of patients with MD (2 male, 1 female, aged 40, 27, and 32 years), and 8 AS and 10 AM results of a single male patient with MCM (age 30 years). Results NM patients had preserved graft function, were on standard immunosuppression and had no significant rejection history or sensitization. There was no statistically significant difference in AM scores between MD and MCM groups. AM scores in the NM group were significantly lower

Author

L. Holzhauser; M. Molina; P. Joshi; P. Atluri; L. Goldberg; R. McLean

Publisher

Elsevier BV

Published

2023

Language

EN